Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label single-arm study of duvelisib in relapsed or refractory follicular lymphoma
CTR20200132Phase 2Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of duvelisib in follicular lymphoma (FL), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Jan 2020; status: active.
02
Drugs
duvelisib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on CTR20200132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200132.